Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

Customers have known for months that the Dexcom G7 continuous glucose monitoring sensor had problems. Now, the company is ...

DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...

New study results could lead to better insurance coverage of the devices for people who don’t take insulin, a researcher said ...

By Sneha S K June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to ...

SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...

Editor’s note: This post was updated on June 9 to include a statment from Pharmsource. People with diabetes who use the Dexcom G7 continuous glucose monitoring system need to check the lot numbers on ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

Dexcom says stolen G7 sensors from two scrapped lots were sold through unauthorized channels, creating infection and reading-failure risks.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation ...

After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...